Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Authors
Keywords
-
Journal
Journal of Personalized Medicine
Volume 12, Issue 7, Pages 1073
Publisher
MDPI AG
Online
2022-06-30
DOI
10.3390/jpm12071073
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-risk triple-negative breast cancers: clinico-pathological and molecular features
- (2022) Nicola Fusco et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A new AI-assisted scoring system for PD-L1 expression in NSCLC
- (2022) Ziling Huang et al. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
- Harmonization of programmed death‐ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis
- (2022) Marie Darmon‐Novello et al. HISTOPATHOLOGY
- Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
- (2022) Kohei Shitara et al. NATURE
- Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022
- (2022) Zishuo Ian Hu et al. Cancers
- Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
- (2022) Matteo Brunelli et al. Journal of Personalized Medicine
- PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside
- (2022) Riccardo Nocini et al. Clinical and Experimental Dental Research
- Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas
- (2021) Carole Pflumio et al. ONCOLOGY REPORTS
- PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
- (2021) Simona Crosta et al. Cancers
- PD‐L1 and beyond: Immuno‐oncology in cytopathology
- (2021) Antonino Iaccarino et al. CYTOPATHOLOGY
- PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
- (2021) Enrico Munari et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy
- (2021) Soomin Ahn et al. MODERN PATHOLOGY
- Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
- (2021) Carmen Criscitiello et al. Anti-Cancer Agents in Medicinal Chemistry
- Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma
- (2021) Zhonghua Liu et al. CANCER CYTOPATHOLOGY
- Challenges facing pathologists evaluating PD‐L1 in head & neck squamous cell carcinoma
- (2021) Ilaria Girolami et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions
- (2021) Rita T. Lawlor et al. Cancers
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
- (2021) Alexander MM. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy
- (2021) Gaetano Paolino et al. PATHOLOGY RESEARCH AND PRACTICE
- Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view
- (2020) Alessia Cimadamore et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cytology for PD-L1 testing: A systematic review
- (2020) John R. Gosney et al. LUNG CANCER
- Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma
- (2020) Ilaria Girolami et al. ENDOCRINE PATHOLOGY
- Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
- (2020) Claudio Luchini et al. GUT
- PD-L1/PD-1 axis as a potent therapeutic target in breast cancer
- (2020) Shima Bastaki et al. LIFE SCIENCES
- PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
- (2020) Wei Xie et al. Current Hematologic Malignancy Reports
- PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
- (2020) Jian-ye Zhang et al. Frontiers in Pharmacology
- Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go
- (2020) Romualdo Barroso-Sousa et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
- (2020) Fabio Pagni et al. Cancers
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†
- (2020) F. Cardoso et al. ANNALS OF ONCOLOGY
- Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
- (2020) Debora de Melo Gagliato et al. BIODRUGS
- Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
- (2020) Robert C Grant et al. GUT
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
- (2020) Nicola Fusco et al. LUNG CANCER
- Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
- (2020) Elizabeth C. Paver et al. PATHOLOGY
- Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
- (2019) Sylvie Lantuejoul et al. Journal of Thoracic Disease
- The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2019) Yan Li et al. Frontiers in Pharmacology
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- 10OComparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC)
- (2019) M Scott et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience
- (2019) Elena Vigliar et al. Biomed Research International
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
- (2019) Fabio Pagni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Current status and limitations of immunotherapy for breast cancer
- (2019) Yoshihisa Tokumaru et al. SURGERY
- PD-L1 expression in gastroesophageal dysplastic lesions
- (2019) Matteo Fassan et al. VIRCHOWS ARCHIV
- PD-L1 assessment in urothelial carcinoma: a practical approach
- (2019) Markus Eckstein et al. Annals of Translational Medicine
- Basis of PD1/PD-L1 Therapies
- (2019) Barbara Seliger Journal of Clinical Medicine
- PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs
- (2018) Enrico Munari et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes
- (2018) Poonam K. Panjwani et al. HUMAN PATHOLOGY
- PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications
- (2018) Claudio Luchini et al. HUMAN PATHOLOGY
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- (2018) Ming Sound Tsao et al. Journal of Thoracic Oncology
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
- (2018) Nina Prokoph et al. Cancers
- The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy
- (2018) Caterina Fumagalli et al. Immunotherapy
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
- (2017) Tomas Jelinek et al. IMMUNOLOGY
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
- (2017) Fred R. Hirsch et al. Journal of Thoracic Oncology
- Whole tumor section quantitative image analysis maximizes between-pathologists’ reproducibility for clinical immunohistochemistry-based biomarkers
- (2017) Michael Barnes et al. LABORATORY INVESTIGATION
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
- (2017) Charlotte Rigaud et al. PEDIATRIC BLOOD & CANCER
- Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
- (2017) Chan-Young Ock et al. Oncotarget
- PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
- (2017) Sylvain Simon et al. OncoImmunology
- Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
- (2016) Thomas S. Y. Chan et al. ANNALS OF HEMATOLOGY
- Cancer Immunology and Immunotherapy
- (2016) AMMAR SUKARI et al. ANTICANCER RESEARCH
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
- (2016) Melanie Straub et al. Oncotarget
- Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
- (2015) Dohee Kwon et al. HISTOPATHOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
- (2014) Min Shi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
- (2009) R. A. Wilcox et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now